Cancer risk assessment of toxaphene

Surasak Buranatrevedh1

  • 1Department of Community Medicine, Faculty of Medicine, Thammasat University, Rangsit Campus, Klongluang, Pathumthani, Thailand.

Industrial Health
|August 7, 2004
PubMed

Insights

This study assessed the cancer risk of the banned insecticide toxaphene using a four-step risk assessment framework. Findings indicate potential carcinogenic risks to humans from average exposure levels.

Area of Science:

  • Environmental Toxicology
  • Chemical Risk Assessment
  • Public Health

Background:

  • Toxaphene was a widely used insecticide globally until its ban in 1982.
  • Previous studies suggest toxaphene exposure is linked to various cancers in animal models.

Purpose of the Study:

  • To evaluate the potential human cancer risk associated with toxaphene exposure.
  • To apply the four-step risk assessment framework developed by the National Academy of Sciences/National Research Council (NAS/NRC).

Main Methods:

  • Hazard identification of toxaphene's carcinogenic potential.
  • Dose-response assessment to determine the slope factor.
  • Exposure assessment considering various environmental pathways (air, water, soil, fish).
  • Risk characterization to quantify cancer risk.

Main Results:

  • Toxaphene exposure increased neoplasms in the liver and uterus of mice.
  • Increased neoplasms in endocrine organs, thyroid, pituitary, adrenal, mammary, and reproductive systems were observed in rats.
  • The calculated slope factor for toxaphene is 0.8557 (mg/kg/day)(-1).
  • Lifetime Average Daily Doses (LADD) varied across exposure routes, with fish posing the highest.
  • The estimated cancer risk for average exposure to toxaphene is 7.42 x 10(-5).

Conclusions:

  • Toxaphene exhibits carcinogenic potential in animal studies.
  • The quantitative risk assessment suggests a potential carcinogenic risk to humans from environmental exposure to toxaphene.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...